

HIC-1 (D-17): sc-10318

BACKGROUND

Hypermethylated in cancer (HIC-1) was originally identified as a target of p53-induced gene expression. HIC-1 is deleted in the genetic disorder Miller-Dieker syndrome (MDS), and the expression of HIC-1 is also frequently suppressed in leukemia and various cancers due to the hypermethylation of specific DNA regions and the resulting transcriptional silencing. These and other studies indicate that HIC-1 acts as a putative tumor suppressor protein that mediates transcriptional repression. HIC-1 is ubiquitously expressed in adult tissues. Its structure is defined by five zinc fingers and an N-terminal broad complex POZ (or BTB) domain. The BTB/POZ domain mediates homomeric and heteromeric POZ-POZ interactions and is common to transcriptional regulators involved in chromatin modeling. In several BTB/POZ containing proteins, including Bcl-6 and the promyelocytic leukemia zinc-finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. Conversely, HIC-1 does not interact with components of the HDAC complex, suggesting that HIC-1-induced transcriptional repression is unassociated with the POZ/BTB domain.

REFERENCES

1. Wales, M.M., et al. 1995. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. *Nat. Med.* 1: 570-577.
2. Ahmad, K.F., et al. 1998. Crystal structure of the BTB domain from PLZF. *Proc. Natl. Acad. Sci. USA* 95: 12123-12128.
3. David, G., et al. 1998. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. *Oncogene* 16: 2549-2556.
4. Huynh, K.D., et al. 1998. The Bcl-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. *Oncogene* 17: 2473-2484.
5. Wong, C.W., et al. 1998. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and Bcl-6. *J. Biol. Chem.* 273: 27695-27702.
6. Guerardel, C., et al. 1999. Evolutionary divergence in the broad complex, tramtrack and bric a brac/poxviruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer. *FEBS Lett.* 451: 253-256.
7. Deltour, S., et al. 1999. Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. *Proc. Natl. Acad. Sci. USA* 96: 14831-14836.

SOURCE

HIC-1 (D-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of HIC-1 of human origin.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-10318 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-10318 X, 200 µg/0.1 ml.

APPLICATIONS

HIC-1 (D-17) is recommended for detection of HIC-1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for HIC-1 siRNA (h): sc-37712, HIC-1 siRNA (m): sc-37713, HIC-1 shRNA Plasmid (h): sc-37712-SH, HIC-1 shRNA Plasmid (m): sc-37713-SH, HIC-1 shRNA (h) Lentiviral Particles: sc-37712-V and HIC-1 shRNA (m) Lentiviral Particles: sc-37713-V.

HIC-1 (D-17) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of HIC-1: 76 kDa.

Positive Controls: KNRK whole cell lysate: sc-2214.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.